Dr. Luwy Musey is currently Director in Biologics, Clinical Research with Merck Research Laboratories. In his position, he is supervising different vaccine clinical research activities for early and late development targets.
Join us on the 11th April at the 12th annual World Vaccine Congress when Dr Musey addresses the issue of assessing current capabilities in emerging countries regarding quality of clinical research programs – Do we need to achieve levels required by regulatory agencies in developed countries?
He will highlight the safety assessment following receipt of the study vaccine. What is the duration of follow-up, reporting of adverse events by study subjects, and causality assessment?
Discuss the incidence of certain medical conditions in the general population to serve as reference for detection of rare safety events, as well as all IP issues that surface when collaborating with scientists or institutions from emerging and developing countries.
All this and much more will be discussed on April 11th 2012.
Get your questions ready!
Have a look at the Congress program here.
Ensure you join us at the event at the best possible ticket price by booking your place before THIS FRIDAY 27th January – register here.